



Siponimod for Secondary Progressive Multiple Sclerosis & Esketamine for Treatment-Resistant Depression

Thursday • May 23, 2019 • 9:00 am to 5:00 pm

LAX Room, Hyatt Regency O'Hare Chicago, 9300 W. Bryn Mawr Ave, Rosemont, IL 60018

Time	Activity
8:30 am—9:00 am	Registration for Public Attendees
9:00 am—9:15 am	Meeting Convened and Opening Remarks Steve Pearson, MD, MSc, President, ICER
Morning Session: Siponimod for Secondary Progressive Multiple Sclerosis	
9:15 am—10:15 am	Presentation of the Evidence <ul style="list-style-type: none"> • Ravi Sharaf, MD, MS, Associate Professor of Medicine, Weill Cornell Medicine • Lisa Bloudek, PharmD, MS, CHOICE Institute, Department of Pharmacy, University of Washington
10:15 am—10:30 am	Manufacturer Comments and Discussion
10:30 am—10:50 am	Public Comments and Discussion
10:50 am – 11:00 am	Break
11:00 am – 11:40 am	Midwest CEPAC Panel Vote on Clinical Effectiveness and Value
11:40 am—12:15 pm	Key Policy Discussion
12:15 pm – 1:00 pm	Lunch
Afternoon Session: Esketamine for Treatment-Resistant Depression	
1:00 pm—1:15 pm	Meeting Reconvened Steve Pearson, MD, MSc, President, ICER
1:15 pm—2:15 pm	Presentation of the Evidence <ul style="list-style-type: none"> • Steven J. Atlas, MD, MPH, Director, Practice Based Research & Quality Improvement, Division of General Internal Medicine, Massachusetts General Hospital • Daniel R. Touchette, PharmD, MA, Professor of Pharmacy; Assistant Director, Center for Pharmacoepidemiology and Pharmaco-economic Research, University of Illinois at Chicago
2:15 pm – 2:30 pm	Public Comments and Discussion
2:30 pm—3:30 pm	Midwest CEPAC Panel Vote on Clinical Effectiveness and Value
3:30 pm – 3:45 pm	Break
3:45 pm – 4:45 pm	Policy Roundtable Discussion
4:45 pm – 5:00 pm	Reflections from Midwest CEPAC Panel/Adjourn



Participating Members of Midwest CEPAC	
<p>Eric Armbrecht, PhD* (Chair) Associate Professor Saint Louis University Center for Health Outcomes Research</p>	<p>Jill Johnson, PharmD* Professor, College of Pharmacy University of Arkansas for Medical Sciences</p>
<p>Nicolas Bagley, JD* Professor of Law University of Michigan Law School</p>	<p>Timothy McBride, PhD* Co-Director, Center for Health Economics and Policy; Professor, Brown School Washington University in St. Louis</p>
<p>Ryan Barker, MSW, MPPA* Vice President of Health Policy Missouri Foundation for Health</p>	<p>Scott Micek, PharmD* Associate Professor Saint Louis College of Pharmacy</p>
<p>Bijan Borah, PhD* Professor of Health Services Research Mayo Clinic College of Medicine and Science</p>	<p>Reem Mustafa, MD, MPH, PhD Associate Professor of Medicine, Division of Nephrology and Hypertension; Director, Outcomes and Implementation Research Saint Louis College of Pharmacy</p>
<p>Aaron Carroll, MD, MS* Professor of Pediatrics; Associate Dean for Research Mentoring; Director, Center for Health Policy and Professionalism Research Indiana University School of Medicine</p>	<p>Harold Pollack, PhD* Helen Ross Professor University of Chicago</p>
<p>Don Casey, MD, MPH, MBA* Principal, IPO4Health Senior Vice President and Chief of Clinical Affairs, Medecision</p>	<p>Kurt Vanden Bosch, PharmD* System Formulary Manager St. Luke's Health System</p>
<p>Gregory Curfman, MD* Deputy Editor Journal of the American Medical Association (JAMA)</p>	<p>Timothy Wilt, MD, MPH* Professor of Medicine; Director, Minnesota Evidence-Based Synthesis Program Minneapolis VA Center for Chronic Disease Outcomes Research</p>
<p>Stacie Dusetzina, PhD* Associate Professor of Health Policy; Ingram Associate Professor of Cancer Research Vanderbilt University School of Medicine</p>	<p>Stuart Winston, DO* Physician Lead: Patient Experience, Quality Improvement, Integrated Health Associates St. Joseph Mercy Health System</p>
<p>Elbert Huang, MD, MPH* Professor of Medicine; Director, Center for Chronic Disease Research and Policy University of Chicago</p>	

*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.



Multiple Sclerosis Key Policy Discussion Participants

Participant	Conflict of Interest
Bruce A. Cohen, MD , Professor, Davee Department of Neurology and Clinical Neurological Sciences, Northwestern University Feinberg School of Medicine	Dr. Cohen has received consulting income from Biogen, Celgene, and EMD Serono and research funding from Roche/Genentech and MedDay. He owns stock in Abbott Laboratories, AbbVie, and CVS Health
Jeremy Fredell, PharmD, BCPS , Director Trend Solutions – Drug Trend & Formulary, Express Scripts	Dr. Fredell is a full-time employee of Express Scripts
Annette Langer-Gould, MD, PhD , Regional Lead for Clinical and Translational Neuroscience, Kaiser Permanente/Southern California Permanente Medical Group	No conflicts of interest to disclose
Ann M. Moore , Patient Advocate	No conflicts of interest to disclose
Hollie Schmidt , Vice President of Scientific Operations, Accelerated Cure Project for Multiple Sclerosis	No conflicts of interest to disclose
Gustavo Suarez-Zambrano, MD , Lead Medical Director (Multiple Sclerosis), Novartis Pharmaceuticals Corporation	Dr. Suarez-Zambrano is a full-time employee of Novartis.

Treatment-Resistant Depression Policy Roundtable Participants

Participant	Conflict of Interest
Cristina Cusin, MD , Assistant Professor in Psychiatry, Massachusetts General Hospital	Dr. Cusin served as site PI for an esketamine trial sponsored by Janssen.
Phyllis Foxworth , Vice President of Advocacy, Depression and Bipolar Support Alliance	No conflicts of interest to disclose
Jeremy Fredell, PharmD, BCPS , Director Trend Solutions – Drug Trend & Formulary, Express Scripts	Dr. Fredell is a full-time employee of Express Scripts
Young Fried, PharmD, MSP , Vice President, Pharmacy Plan Services, HealthPartners	Dr. Fried is a full-time employee of HealthPartners.
William S. Gilmer, MD , Clinical Professor of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine	Dr. Gilmer has received consulting and speaker fee honorarium from Sunovion and Otsuka; and owns equity in Organovo, Jounce, and Gilead.
Pamela Goloskie , Patient Advocate	No conflicts of interest to disclose



ICER Staff and Consultants*	
Ellie Adair, MPA , Program Manager, ICER	Noemi Fluetsch, MPH , Research Assistant, ICER
Foluso Agboola, MBBS, MPH , Director, Evidence Synthesis, ICER	Maggie O’Grady , Program and Event Coordinator, ICER
Steven J. Atlas, MD, MPH , Director, Practice Based Research & Quality Improvement, Division of General Internal Medicine, Massachusetts General Hospital	Steve Pearson, MD, MSc , President, ICER
Lisa Bloudek, PharmD, MS , CHOICE Institute, Department of Pharmacy, University of Washington	David Rind, MD, MSc , Chief Medical Officer, ICER
Nicole Boyer, PhD , Research Fellow, University of Chicago	Ravi Sharaf, MD, MS , Associate Professor of Medicine, Weill Cornell Medicine
Pamela Bradt, MD, MPH , Chief Scientific Officer, ICER	Patty Synnott, MALD, MS , Director, Evidence Review, ICER
Josh J. Carlson, PhD, MPH , Associate Professor, CHOICE Institute, Department of Pharmacy, University of Washington	Daniel R. Touchette, PharmD, MA , Professor of Pharmacy; Assistant Director, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago
Katherine Fazioli , Senior Research Assistant, ICER	

*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.